Showing results (411-420 of 587) with videos related to
Sort By:
Pageof 59
The Lancet. Oncology|January 21, 2019
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trialArnaud Scherpereel, Julien Mazieres, Laurent Greillier, et al.The Lancet. Oncology|November 1, 2019
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trialAlice T Shaw, Benjamin J Solomon, Rita Chiari, et al.Autoimmunity Reviews|January 10, 2020
Systemic lupus erythematosus associated with thymoma: A fifteen-year observational study in FranceNicolas Noël, Audrey Le Roy, Arnaud Hot, et al.Nature Reviews. Clinical Oncology|March 15, 2025
Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trialsSophie M Ernst, Mihaela Aldea, Jan H von der Thüsen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2024
Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven MalignanciesFrancesco Facchinetti, Yohann Loriot, Floriane Brayé, et al.Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutationJean Bernard Auliac, Maurice Pérol, David Planchard, et al.European Journal of Cancer (Oxford, England : 1990)|September 27, 2021
Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicitiesSamia Hajem, Stéphane Ederhy, Stéphane Champiat, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2013
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectivesJulien Mazières, Solange Peters, Benoit Lepage, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 2, 2010
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lungNatasha B Leighl, Luis E Raez, Benjamin Besse, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014
Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTEMarie Wislez, Fabrice Barlesi, Benjamin Besse, et al.Pageof 59